Surgical experimental neurotherapeutics

Introduction to Neurotherapeutics and Neuropsychopharmacology

In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology o...

Review Article for Expert Review of Neurotherapeutics

Epilepsy is a neurological disorder characterized by the recurrence of seizures. It affects 50 million people worldwide. Although a considerable number of new anti-epileptic drugs with reduced side-effects and toxicity have been introduced since the 1950s, 30% of patients remain pharmacoresistant. Although epilepsy research is making progress, advances in understanding the drug resistance have ...

Delivery of neurotherapeutics across the blood brain barrier in stroke.

Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. ...

Intranasal Delivery of Nano Neurotherapeutics: A Meta Opinion

The most stringer barrier for the delivery of neurotherapeutics in-vivo is presented by the blood-brain barrier which limits the access of neurotherapeutics to the CNS effectively. Intranasal delivery of neurotherapeutics is one of the promising endeavors to surmount the blood-brain barrier, designated as direct nose to brain transport, by the passage of neurotherapeutics along the olfactory an...

An Experimental Research into Surgical Shock